IgG1 anti‐epidermal growth factor receptor antibodies induce CD8‐dependent antitumor activity. Issue 4 (26th June 2014)

• Record Type: Journal Article
• Authors: Kubach, Jan; Hubo, Mario; Amendt, Christiane; Stroh, Christopher; Jonuleit, Helmut
• Is Part Of: International journal of cancer. Volume 136:Issue 4(2015:Feb. 15)
• Page Start: 821
• Page End: 830
• Publication Date: 2014-06-26
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29037
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Anti‐EGFR monoclonal antibodies (mAb) like Cetuximab are commonly used for treatment of EGFR<sup>+</sup> solid tumors mainly by exerting their therapeutic effect through inhibition of signal transduction. Additionally, IgG1 is a potent mediator of antibody‐dependent cytotoxicity (ADCC). In case of the IgG1, Cetuximab induction of ADCC <italic>in vivo</italic> is controversially discussed. In our study, we investigated the efficiency of Cetuximab‐mediated ADCC in a humanized mouse tumor model <italic>in vivo</italic> and analyzed the contribution of immunologic processes toward antitumor activity. Therefore, we used immunodeficient NOD/<italic>Scid</italic> mice transgenic for human MHC class I molecule HLA‐A2 and adoptively transferred human HLA‐A2<sup>+</sup> PBMC after engraftment of human epidermoid cell carcinoma A431. Here, we show that high doses of anti‐EGFR mAb induced strong tumor regression independent of the immune system. However, tumor regression by low doses of anti‐EGFR mAb treatment was ADCC dependent and mediated by tumor infiltrating CD8<sup>+</sup> T effector cells. This novel mechanism of ADCC conducted by CD8<sup>+</sup> T effector cells was restricted to IgG1 anti‐EGFR mAb, dependent of binding to CD16 on T cells and could be inhibited after EGFR blockade on tumor cells. Furthermore, CD8<sup>+</sup> T effector cell‐mediated ADCC was enhanced in the presence of IL‐15 and strongly improved after glycosylation of anti‐EGFR mAb indicating the potential of glycoengineered therapeutic mAb as efficient biologicals in cancer therapy.</p> </abstract>